

Macromolecole della risposta alla pressione parziale di ossigeno (3)

In mammals, **O₂ sensing** leads to **chronic**
(days ...weeks) adaptation






Fig 1. The hypoxia-inducible factor (HIF) transcriptional cascade directly regulates genes with key functions in a broad range of processes. The complex binds in a sequence-specific manner to control elements in DNA, termed hypoxia-response elements, at target gene loci.





Quesiti

UBIQUITINA




VHL Function: the difference in K_D for hydroxylated versus non-hydroxylated CODD is $\sim 1,000$ -fold (33 nM versus 34 μ M)






Cul2 recruits pVHL at its N-terminal region through an adaptor subunit constituted by a dimeric complex formed by Elongin B (EloB) and Elongin C (EloC)







Cullin RING E3 ubiquitin ligases catalyze the transfer of ubiquitin from the E2-conjugating enzyme to the target substrate

the E2 enzyme loaded with ubiquitin is recruited by the RING finger protein Rbx1




Substrate
HIF-1



Quesiti

Regulation of prolyl hydroxylase domain (PHD) enzyme activity


INHIBITORS




INIBITORI FARMACOLOGICI DI PHD

activation of the HIF response by PHD inhibition

A Normoxia






B Hypoxia




FG-4592 acts as competitive antagonists of 2-oxoglutarate, a cofactor that accepts one oxygen from molecular dioxygen to become succinate as the second oxygen forms trans-4-hydroxyproline

PHD inhibitor

Normoxia



Effect of Roxadustat on neural retina apoptosis.



outer nuclear layer (ONL),
inner nuclear layer (INL)
ganglion cell layer (GCL)

RXD?
+EPO
-Apoptosis


Quantification of active caspase 3-positive cells demonstrates statistically significant reduction in apoptosis in the inner nuclear layer of animals treated with **Roxadustat (RXD)** FG-4592

George Hoppe et al. PNAS 2016;113:E2516-E2525

PNAS

Respiratory Chain inhibition

A




Isha H. Jain et al. *Science* 2016;352:54-61



FG-4592 treatment activates the HIF response in zebrafish embryos and alleviates death caused by Respiratory Chain inhibition.

Isha H. Jain et al. Science 2016;352:54-61

Antimycin=Anti
Respiratory Chain inhibition




RC inhibition by 2.5 nM antimycin in 4 days post fertilization (dpf) embryos results in significant death within the first 24 hours of treatment

Coexposure of antimycin with FG-4592 (2.5 μ M) doubles embryo survival, whereas FG-4592 alone has no impact.


Exposure to FG-4592 rescues antimycin-induced zebrafish embryonic death.

HIF Metabolismo e Mitocondrio


HIF transcription factor effects




HIFa Control of Cell Metabolism




HIFa Control of Cell Metabolism



HIFa Control of Cell Metabolism



decrease the oxidation of pyruvate in mitochondria and increase the conversion of pyruvate to lactate in the cytosol



How to model Mitochondrial disease

Delivery of Cas9 and sgRNA provides efficient depletion of target genes


synthetic single-guide RNA (sgRNA) targeted to specific coding regions of genes

programming the CRISPR (clustered regularly interspaced short palindromic repeats)–associated nuclease Cas9 to modify specific genomic loci

Design of sgRNA library for genome-scale knockout of coding sequences in human cells


A

Step 1:
sgRNA oligo
library design




CRISPR library sgRNAs targeting exons of 18,080 genes in the human genome with an average coverage of 3 to 4 sgRNAs per gene

genome-scale **screening**




PCR amplification «sgRNAs» HiSeQ

Genome-scale Cas9-mediated knockout screen during states of mitochondrial dysfunction.



Mitochondrial disease was modeled with the addition of the complex III inhibitor antimycin (moderate disease)
addition of antimycin and **removal of pyruvate (severe disease S)**.

Genome-scale Cas9-mediated knockout screen during states of mitochondrial dysfunction.



cells were infected with the genome-scale Cas9-mediated knockout library


3 conditions U untreated, M moderate disease, S severe disease

Samples were taken at a **pretreatment time point** and **after 3 weeks of selection**



genome-scale **screening**

enrichment of sgRNAs



PCR amplification «sgRNAs» HiSeq


Genome-scale Cas9-mediated knockout screen identifies VHL inhibition as protective during states of mitochondrial dysfunction.

enrichment of sgRNAs in severe disease **S** relative to pretreatment conditions **U**


D

| Gene | sgRNA Ranks | Rank |
|---------|--------------------------------------|------|
| VHL | 1, 2, 3, 12, 14 | 1 |
| RGS20 | 13, 145, 2266, 8296, 27675, 29239 | 2 |
| SIN3A | 32, 242 | 3 |
| ESPNL | 168, 199, 8244, 8519, 12532, 58512 | 4 |
| EXOC3L4 | 47, 267, 6259, 7589 | 5 |
| DOCK7 | 177, 299, 4796, 10550, 18350, 23644 | 6 |
| NDUFS6 | 8, 403, 2876, 7677 | 7 |
| CLSTN1 | 7, 412, 11644, 46491 | 8 |
| CD101 | 139, 372, 14840, 30593, 57365, 61388 | 9 |
| TRIO | 277, 342, 1831, 23700, 37855 | 10 |

E




vhl KO activates the HIF response in zebrafish embryos and alleviates death caused by RC inhibition.



Anti = Respiratory Chain inhibition




Mutations in mitochondrial disease



| OXPHOS Component | Complex I | Complex II | Complex III | Complex IV | Complex V |
|---|---|--|---|--|---|
| mtDNA structural subunit genes | <i>MTND1</i> [120] <i>MTND2</i> [121] <i>MTND3</i> [122] <i>MTND4</i> [123] <i>MTND4L</i> [124] <i>MTND5</i> [125] <i>MTND6</i> [126] | - | <i>MTCYB</i> [127] | <i>MTCO1</i> [128] <i>MTCO2</i> [129] <i>MTCO3</i> [130] | <i>MTATP6</i> [131] <i>MTATP8</i> [132] |
| Nuclear structural subunit genes | <i>NDUFS1</i> [133] <i>NDUFS2</i> [134] <i>NDUFS3</i> [135] <i>NDUFS4</i> [136] <i>NDUFS5</i> <i>NDUFS6</i> [137] <i>NDUFS7</i> [138] <i>NDUFS8</i> [139] <i>NDUFA1</i> [140] <i>NDUFA2</i> [141] <i>NDUFA3</i> <i>NDUFA5</i> <i>NDUFA6</i> <i>NDUFA7</i> <i>NDUFA8</i> <i>NDUFA9</i> [142] <i>NDUFA10</i> [143] <i>NDUFA11</i> [21] <i>NDUFA12</i> [144] <i>NDUFA13</i> [145] <i>NDUFAB1</i> <i>NDUFV1</i> [146] <i>NDUFV2</i> [147] <i>NDUFV3</i> <i>NDUFB1</i> <i>NDUFB2</i> <i>NDUFB3</i> [148] <i>NDUFB4</i> <i>NDUFB5</i> <i>NDUFB6</i> <i>NDUFB7</i> <i>NDUFB8</i> <i>NDUFB9</i> [149] <i>NDUFB10</i> <i>NDUFB11</i> [150] <i>NDUFC1</i> <i>NDUFC2</i> | <i>SDHA</i> [25] <i>SDHB</i> [151] <i>SDHC</i> <i>SDHD</i> [152] | <i>UQCRB</i> [153] <i>UQCRC1</i> <i>CYC1</i> [156] <i>UQCRC2</i> [154] <i>UQCRFS1</i> <i>UQCRH</i> <i>UQCQRQ</i> [155] <i>UQCR10</i> <i>UQCR11</i> | <i>COX4</i> [157] <i>COX5A</i> <i>COX5B</i> <i>COX6A</i> [57] <i>COX6B</i> [158] <i>COX6C</i> <i>COX7A</i> <i>COX7B</i> [159] <i>COX7C</i> <i>COX8</i> [160] | <i>ATP5A1</i> [76] <i>ATP5B</i> <i>ATP5C1</i> <i>ATP5D</i> <i>ATP5E</i> [161] <i>ATP5F1</i> <i>ATP5G1</i> <i>ATP5G2</i> <i>ATP5G3</i> <i>ATP5H</i> <i>ATP5I</i> <i>ATP5O</i> <i>ATP5J</i> <i>ATP5J2</i> <i>ATP5L</i> <i>ATP5L2</i> |
| Assembly factor and ancillary protein genes | <i>NDUFAF1</i> [162] <i>NDUFAF2</i> [163] <i>NDUFAF3</i> [164] <i>NDUFAF4</i> [165] <i>NDUFAF5</i> [166] <i>NDUFAF6</i> [167] <i>NDUFAF7</i> <i>FOXRED1</i> [168] <i>ACAD9</i> [30] <i>ECSIT</i> <i>NUBPL</i> [168] <i>TMEM126B</i> [28, 37] <i>TIMMDC1</i> <i>C17orf89</i> | <i>SDHAF1</i> [41] <i>SDHAF2</i> <i>SDHAF3</i> <i>SDHAF4</i> | <i>BCS1L</i> [49] <i>LYRM7</i> [169] <i>UQCC1</i> <i>UQCC2</i> [170] <i>UQCC3</i> [171] <i>TTC19</i> [172] <i>PTCD2</i> | <i>COA1</i> <i>COA3</i> [173] <i>COA4</i> <i>COA5</i> [174] <i>COA6</i> [175] <i>COA7</i> <i>COX10</i> [176] <i>COX11</i> <i>COX14</i> [177] <i>COX15</i> [178] <i>COX16</i> <i>COX17</i> <i>COX18</i> <i>COX19</i> <i>COX20</i> [179] <i>SCO1</i> [180] <i>SCO2</i> [181] <i>SURF1</i> [182] <i>PET117</i> <i>LRPPRC</i> [183] <i>PET100</i> [184] <i>CEP89</i> [185] <i>TACO1</i> [186] <i>OXA1L</i> <i>APOPT1</i> [187] <i>NDUFA4</i> [53] <i>FASTKD2</i> [188] | <i>ATPAF1</i> <i>ATPAF2</i> [189] <i>TMEM70</i> [58] |


bold= genes
with mutations



| OXPHOS Component | Complex I |
|----------------------------------|--|
| mtDNA structural subunit genes | <i>MTND1</i> [120] <i>MTND2</i> [121] <i>MTND3</i> [122] <i>MTND4</i> [123] <i>MTND4L</i> [124] <i>MTND5</i> [125] <i>MTND6</i> [126] |
| Nuclear structural subunit genes | <i>NDUFS1</i> [133] <i>NDUFS2</i> [134] <i>NDUFS3</i> [135] <i>NDUFS4</i> [136] <i>NDUFS5</i> <i>NDUFS6</i> [137] <i>NDUFS7</i> [138] <i>NDUFS8</i> [139] <i>NDUFA1</i> [140] <i>NDUFA2</i> [141] <i>NDUFA3</i> <i>NDUFA5</i> <i>NDUFA6</i> <i>NDUFA7</i> <i>NDUFA8</i> <i>NDUFA9</i> [142] <i>NDUFA10</i> [143] <i>NDUFA11</i> [21] <i>NDUFA12</i> [144] <i>NDUFA13</i> [145] <i>NDUFAB1</i> <i>NDUFV1</i> [146] <i>NDUFV2</i> [147] <i>NDUFV3</i> <i>NDUFB1</i> <i>NDUFB2</i> <i>NDUFB3</i> [148] <i>NDUFB4</i> <i>NDUFB5</i> <i>NDUFB6</i> <i>NDUFB7</i> <i>NDUFB8</i> <i>NDUFB9</i> [149] <i>NDUFB10</i> <i>NDUFB11</i> [150] <i>NDUFC1</i> <i>NDUFC2</i> |

Mouse model of Leigh syndrome *Ndufs4* ^{-/-} (KO) NADH:ubiquinone oxidoreductase subunit S4

Chronic hypoxia extends life span and alleviates disease in a mouse model of Leigh syndrome (KO) .





chronic hyperoxia
exacerbates disease

Isha H. Jain et al. Science 2016;352:54-61




Fig. 5 Chronic hypoxia extends life span and alleviates disease in a mouse model of Leigh syndrome (KO) whereas chronic hyperoxia exacerbates disease.



Isha H. Jain et al. *Science* 2016;352:54-61

Breathing 11% O₂ in late-stage neurological disease **reverses** pathological inflammation in the brains of Ndufs4 KO mice.

Iba-1 staining=pathological inflammation



KO mice breathing 21% O₂ up to 55 d and then breathing 11% O₂ to 160 d.


Iba-1 is up-regulated in microglia following nerve injury, central nervous system ischemia, and several other brain diseases

Genome-scale Cas9-mediated knockout screen and states of mitochondrial dysfunction.

enrichment of sgRNAs in severe disease **S** relative to pretreatment conditions **U**

D

| Gene | sgRNA Ranks | Rank |
|---------------|--------------------------------------|------|
| VHL | 1, 2, 3, 12, 14 | 1 |
| RGS20 | 13, 145, 2266, 8296, 27675, 29239 | 2 |
| SIN3A | 32, 242 | 3 |
| ESPNL | 168, 199, 8244, 8519, 12532, 58512 | 4 |
| EXOC3L4 | 47, 267, 6259, 7589 | 5 |
| DOCK7 | 177, 299, 4796, 10550, 18350, 23644 | 6 |
| NDUFS6 | 8, 403, 2876, 7677 | 7 |
| CLSTN1 | 7, 412, 11644, 46491 | 8 |
| CD101 | 139, 372, 14840, 30593, 57365, 61388 | 9 |
| TRIO | 277, 342, 1831, 23700, 37855 | 10 |



Ndufs6 NADH:ubiquinone oxidoreductase subunit S6

Genome-scale Cas9-mediated knockout screen and states of mitochondrial dysfunction.

enrichment of sgRNAs in severe disease **S** relative to pretreatment conditions **U**

D

| Gene | sgRNA Ranks | Rank |
|---------|--------------------------------------|------|
| VHL | 1, 2, 3, 12, 14 | 1 |
| RGS20 | 13, 145, 2266, 8296, 27675, 29239 | 2 |
| SIN3A | 32, 242 | 3 |
| ESPNL | 168, 199, 8244, 8519, 12532, 58512 | 4 |
| EXOC3L4 | 47, 267, 6259, 7589 | 5 |
| DOCK7 | 177, 299, 4796, 10550, 18350, 23644 | 6 |
| NDUFS6 | 8, 403, 2876, 7677 | 7 |
| CLSTN1 | 7, 412, 11644, 46491 | 8 |
| CD101 | 139, 372, 14840, 30593, 57365, 61388 | 9 |
| TRIO | 277, 342, 1831, 23700, 37855 | 10 |

Sin3A= global transcription regulators
platform for chromatin-modifying activities

Within 24 h of reoxygenation, the hypoxia-induced transcription returned to basal levels
the nucleosome structure was reassembled in the hypoxia-inducible form

Nucleosome reassembly required the transcriptional coregulator SIN3A